Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) announced that results of two new preclinical studies evaluating novel combinations of TH-302, its investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE